{
    "body": "What are PD-1 inhibitors?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27534574", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25682878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22740686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26775720", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27936870", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26588948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26177645", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26581237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18203952", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26567614", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27310809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24402925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27059553", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27063329", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27729774", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23032366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26598057", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27622603", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25823918", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26477470", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27573048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26850630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26041735"
    ], 
    "ideal_answer": [
        "The programmed death-1 (PD-1) pathway negatively regulates T-cell activation and has an important role in regulating antitumor host immunity. Monoclonal antibodies directed against PD-1 or the PD-1 ligand (PD-L1) are used to treat cancer. "
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061026", 
        "http://www.uniprot.org/uniprot/PDCD1_MOUSE"
    ], 
    "type": "summary", 
    "id": "58a3196360087bc10a00000b", 
    "snippets": [
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 354, 
            "text": " The programmed death-1 (PD-1) pathway negatively regulates T-cell activation and has an important role in regulating antitumor host immunity. Monoclonal antibodies directed against PD-1 or the PD-1 ligand (PD-L1) have shown activity in several tumor types with preliminary data suggesting a relationship between PD-L1 expression and response.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775720", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 121, 
            "offsetInEndSection": 329, 
            "text": "Pembrolizumab is a selective humanized IgG4 kappa monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor, an integral component of immune checkpoint regulation in the tumor microenvironment.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26588948", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 163, 
            "text": "Checkpoint inhibitors with monoclonal antibodies targeting the CTLA-4 or PD-1 axis have revolutionized treatment in some solid tumors, especially melanoma and lung", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26581237", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 201, 
            "text": "In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850630", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 481, 
            "offsetInEndSection": 618, 
            "text": "Nivolumab and pembrolizumab target programmed cell death protein 1 (PD-1) receptors and have proven to be superior to ipilimumab alone. T", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850630", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 70, 
            "text": "The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25823918", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 570, 
            "offsetInEndSection": 738, 
            "text": "PD-1 inhibitors are also poised to become standard of care treatment for other cancers, including non-small cell lung cancer, renal cell carcinoma and Hodgkins lymphoma", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682878", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 39, 
            "text": "PD-1 inhibitors raise survival in NSCLC", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402925", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 40, 
            "text": "PD-1 inhibitors raise survival in NSCLC.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402925", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 99, 
            "text": "PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18203952", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 268, 
            "text": "The development of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) checkpoint inhibitors has changed the landscape of non-small-cell lung cancer (NSCLC) therapy, with 2 approvals from the US Food and Drug Administration of PD-1 inhibitors for second-line therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27310809", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 205, 
            "offsetInEndSection": 506, 
            "text": "In this article, we will review the unique biologic features that predispose cHL to PD-1 inhibition, current data regarding the safety and efficacy of PD-1 inhibitors in the treatment of cHL, biomarkers of immune response, ongoing clinical trials with PD-1 inhibitors, as well as areas of uncertainty.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622603", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 192, 
            "offsetInEndSection": 368, 
            "text": "To determine how PD-1 signaling inhibits T cell proliferation, we used human CD4(+) T cells to examine the effects of PD-1 signaling on the molecular control of the cell cycle.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22740686", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 87, 
            "text": "PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032366", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 236, 
            "text": "The field of immuno-oncology has witnessed unprecedented success in recent years, with several programmed cell death 1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936870", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 174, 
            "text": "The use of antibodies against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, has dramatically improved the prognosis of patients with advanced melanoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291635", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 126, 
            "offsetInEndSection": 420, 
            "text": " Since 2010, treatment options for metastatic melanoma have been developed including chemotherapies, checkpoint inhibition immunotherapies, e.g., anti\u2011cytotoxic T\u2011lymphocyte antigen\u20114\u00a0(CTLA\u20114) and anti\u2011programmed death\u20111\u00a0(PD\u20111), and molecular-targeted therapies, e.g., BRAF and MEK inhibitors. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573048", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1455, 
            "offsetInEndSection": 1686, 
            "text": "his strategy may be particularly advantageous for vaccines targeting prostate cancer, a disease for which antitumor vaccines have demonstrated clinical benefit and yet PD-1 pathway inhibitors alone have shown little efficacy to dat", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26041735", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 141, 
            "text": "Manipulation of co-stimulatory or co-inhibitory checkpoint proteins allows for the reversal of tumor-induced T-cell anergy observed in cancer", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26567614", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 130, 
            "text": "Colorectal cancers (CRCs) have been identified as potential targets for immunotherapy with programmed cell death (PD)-1 inhibitors", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27553906", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 300, 
            "text": "Blockading the interaction of programmed death-1 (PD-1) protein with its ligands (PD-Ls, such as PD-L1) was proved to be a pathway for suppressing the development of tumors and other degradations of biological species. Thus, finding PD-1 inhibitors situated at the convergence point of drug discovery", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27063329", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 124, 
            "text": "Anti-programmed cell death receptor-1 (PD-1) antibodies have demonstrated antitumor activity in many cancer entitie", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729774", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 135, 
            "text": " Emerging agents blocking the programmed cell death 1 (PD-1) pathway show activity in metastatic clear cell renal cell carci", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27059553", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 267, 
            "offsetInEndSection": 424, 
            "text": "The effectiveness of a CTLA-targeted antibody in treating melanoma was an impetus for the use of programmed cell death-1 (PD-1) inhibitors in cancer treatmen", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598057", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 189, 
            "text": " Monoclonal antibodies that target the programmed death-1 (PD-1)/programmed death-ligand 1(PD-L1) pathway have shown antitumour activity in metastatic renal cell carcinoma (mRCC)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346135", 
            "endSection": "abstract"
        }
    ]
}